Document ID: chunk:federal_register_of_legislation:F2025C00158:clause:4_1:p81
Version: federal_register_of_legislation:F2025C00158
Segment Type: clause
Provision Reference: sch 4 cl 1 (pt 81/191)
Character Range: 10426289–10439534

chronic spasticity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Compliance with Authority Required procedures - Streamlined Authority Code 7152
                                                                                                                                                                                                                               Patient must have failed to respond to treatment with oral antispastic agents; or
                                                                                                                                                                                                                               Patient must have had unacceptable side effects to treatment with oral antispastic agents; AND
                                                                                                                                                                                                                               Patient must have chronic spasticity of cerebral origin.
C7153               P7153          CN7153           Baclofen                                                                                                                                                                   Severe chronic spasticity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Compliance with Authority Required procedures - Streamlined Authority Code 7153
                                                                                                                                                                                                                               Patient must have failed to respond to treatment with oral antispastic agents; or
                                                                                                                                                                                                                               Patient must have had unacceptable side effects to treatment with oral antispastic agents; AND
                                                                                                                                                                                                                               Patient must have chronic spasticity due to spinal cord injury.
C7164               P7164          CN7164           Goserelin                                                                                                                                                                  Anticipated premature ovarian failure
                                                                                                                                                                                                                               Patient must be receiving treatment with an alkylating agent for a malignancy or an autoimmune disorder that has a high risk of causing premature ovarian failure; AND
                                                                                                                                                                                                                               Patient must not receive more than 6 months' of treatment for this condition in a lifetime;
                                                                                                                                                                                                                               Patient must be pre-menopausal.
C7258               P7258          CN7258           Eribulin                                                                                                                                                                   Advanced (unresectable and/or metastatic) liposarcoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Compliance with Authority Required procedures - Streamlined Authority Code 7258
                                                                                                                                                                                                                               Initial treatment
                                                                                                                                                                                                                               Patient must have an ECOG performance status of 2 or less; AND
                                                                                                                                                                                                                               The condition must be dedifferentiated, myxoid, round-cell or pleomorphic subtype; AND
                                                                                                                                                                                                                               Patient must have received prior chemotherapy treatment including an anthracycline and ifosfamide (unless contraindicated) for this condition; AND
                                                                                                                                                                                                                               The treatment must be the sole PBS-subsidised therapy for this condition;
                                                                                                                                                                                                                               Patient must be aged 18 years or older.
C7273               P7273          CN7273           Icatibant                                                                                                                                                                  Anticipated emergency treatment of an acute attack of hereditary angioedema                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Compliance with Authority Required procedures
                                                                                                                                                                                                                               Initial
                                                                                                                                                                                                                               Patient must have confirmed diagnosis of C1-esterase inhibitor deficiency; AND
                                                                                                                                                                                                                               Patient must have been assessed to be at significant risk of an acute attack of hereditary angioedema; AND
                                                                                                                                                                                                                               The condition must be assessed by a clinical immunologist.  or
                                                                                                                                                                                                                               The condition must be assessed by a respiratory physician.  or
                                                                                                                                                                                                                               The condition must be assessed by a specialist allergist.  or
                                                                                                                                                                                                                               The condition must be assessed by a general physician experienced in the management of patients with hereditary angioedema.
                                                                                                                                                                                                                               The name of the specialist consulted must be provided at the time of application for initial supply.
                                                                                                                                                                                                                               The date of the pathology report and name of the Approved Pathology Authority must be provided at the time of application.
C7274               P7274          CN7274           Icatibant                                                                                                                                                                  Anticipated emergency treatment of an acute attack of hereditary angioedema                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Compliance with Authority Required procedures
                                                                                                                                                                                                                               Continuing
                                                                                                                                                                                                                               Patient must have previously received PBS-subsidised treatment with this drug for this condition.
C7275               P7275          CN7275           Vitamins, minerals and trace elements formula                                                                                                                              Dietary management of conditions requiring a highly restrictive therapeutic diet
                                                                                                                                                                                                                               Patient must have insufficient vitamin and mineral intake due to a specific diagnosis requiring a highly restrictive therapeutic diet; AND
                                                                                                                                                                                                                               Patient must be unable to adequately meet